Provided herein are methods of treating cancer in a patient comprising administering a total daily dose of 240 mg sotorasib to the patient, wherein the cancer is a KRAS G12C mutated cancer. Also provided herein are methods of treating KRAS G12C mutated cancer in a patient comprising administering a total daily dose of 960 mg sotorasib to the patient, and reducing the total daily dose of sotorasib to 480 mg in a patient experiencing an adverse event to the 960 mg dose of sotorasib.

Described herein are compositions and methods for treating constipation in an individual. In some embodiments, the composition and method for treating constipation comprises providing an individual with a therapeutic that comprises a food item and a laxative.

The present composition provides for mitigating adverse effects of alcohol consumption. The composition includes a fructose source comprising between 5% and 75% of a total weight of the composition, a niacinamide source comprising between 0.1% and 1% of the total weight, and a glycoprotein source comprising between 0.1% and 2% of the total weight, wherein the total weight is a weight prior to inclusion with a hydrating source. The composition can be disposed in a powder or dissolved form, as part of a concentrate, and/or part of a beverage. The composition can include mixability for diluting or mixing with the liquid or beverage for user consumption and absorprtion.

The present composition provides for mitigating adverse effects of alcohol consumption. The composition includes a fructose source comprising between 5% and 75% of a total weight of the composition, a niacinamide source comprising between 0.1% and 1% of the total weight, and a glycoprotein source comprising between 0.1% and 2% of the total weight, wherein the total weight is a weight prior to inclusion with a hydrating source. The composition can be disposed in a powder or dissolved form, as part of a concentrate, and/or part of a beverage. The composition can include mixability for diluting or mixing with the liquid or beverage for user consumption and absorprtion.

The present composition provides for mitigating adverse effects of alcohol consumption. The composition includes a fructose source comprising between 5% and 75% of a total weight of the composition, a niacinamide source comprising between 0.1% and 1% of the total weight, and a glycoprotein source comprising between 0.1% and 2% of the total weight, wherein the total weight is a weight prior to inclusion with a hydrating source. The composition can be disposed in a powder or dissolved form, as part of a concentrate, and/or part of a beverage. The composition can include mixability for diluting or mixing with the liquid or beverage for user consumption and absorprtion.

An object of the present invention is to provide a highly effective method for treatment/remission of cancer, and prevention of recurrence/metastasis of cancer at low cost and with few side effects. A composition containing a urinary alkalinization agent, for use in treatment or remission of cancer, or prevention of recurrence or metastasis of cancer.

An object of the present invention is to provide a highly effective method for treatment/remission of cancer, and prevention of recurrence/metastasis of cancer at low cost and with few side effects. A composition containing a urinary alkalinization agent, for use in treatment or remission of cancer, or prevention of recurrence or metastasis of cancer.

The present disclosure provides immunomodulatory fusion proteins-metal hydroxide complexes comprising an immunomodulatory domain adsorbed to a metal hydroxide via ligand exchange. The disclosure also features compositions and methods of using the same, for example, to treat cancer.

The present disclosure provides immunomodulatory fusion proteins-metal hydroxide complexes comprising an immunomodulatory domain adsorbed to a metal hydroxide via ligand exchange. The disclosure also features compositions and methods of using the same, for example, to treat cancer.

This invention is referred to the field of medicine, namely preventative treatment, and may be used as a means of synergetic minimization of negative impact of flights on human health (brain, stomach, lungs, blood vessels, heart etc.) with application of known substances and medicines with newly discovered pharmacological properties in new conditions. The ultimate technical solution of this invention would be synergetic minimization of negative impact of flying on human health without foot swelling, belching, jet-lag, tiredness and fatigue etc. The claimed technical result is achieved by the method of synergetic minimization of negative impact of air flights on human health, including consumption of substances that improve osmotic concentration of blood plasma, in the form of oral rehydration solution, split into two intakes as a minimum, first intake in the amount of at least 0.3 liters up to 1 liter before boarding and further during the flight from half an hour to 2 hours at least 0.3 liters to 1 liter and on as-needed basis.